A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2019
Price : $35 *
At a glance
- Drugs Lisocabtagene-maraleucel (Primary) ; Antineoplastics
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms TRANSCEND - OUTREACH
- Sponsors Juno Therapeutics
- 08 Dec 2019 Results published in the Bristol-Myers Squibb Media Release
- 06 Nov 2019 Results of patients treated in the TRANSCEND, OUTREACH and PILOT studies released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 06 Sep 2019 Planned number of patients changed from 50 to 80.